Dr. Alaa Al-Awamleh is a distinguished Regulatory Affairs Specialist and Doctor of Pharmacy with over a decade of experience in pharmaceutical regulation. Since November 2024, she has served as the Section Head of the Originator Drugs Unit at the Jordan Food and Drug Administration (JFDA), where she leads the Committee of Post-Approval Changes for Originator Drugs and chairs the Local Generics Drug Registration Committee. She also acts as the Focal Point of Contact representing the JFDA Marketing Authorization function in the WHO Global Benchmarking Project, contributing to the authority’s ongoing efforts to achieve Maturity Level 3.

Prior to her current role, Dr. Alaa served as a Senior Regulatory Affairs Specialist at the JFDA from March 2016, where she was responsible for reviewing and assessing electronic Common Technical Dossier (eCTD) files for drug registrations and evaluating post-approval changes of registered drugs. She played an active role in the development and issuance of reliance regulations and guidelines adopted by the JFDA, while conducting thorough assessments of medicine profiles to ensure compliance with safety and efficacy standards.

Dr. Alaa holds a Bachelor of Doctor of Pharmacy from the University of Jordan and built her foundational expertise through clinical roles in hospital and community pharmacy settings between 2012 and 2016. Committed to public health excellence, she continues to drive regulatory efficiency, provide strategic guidance to stakeholders, and ensure that only safe and effective medicines reach the Jordanian market.